Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 302

1.

A randomised trial in malignant mesothelioma (M) of early (E) versus delayed (D) chemotherapy in symptomatically stable patients: the MED trial.

O'Brien ME, Watkins D, Ryan C, Priest K, Corbishley C, Norton A, Ashley S, Rowell N, Sayer R.

Ann Oncol. 2006 Feb;17(2):270-5. Epub 2005 Nov 29.

2.

Cisplatin versus carboplatin in combination with mitomycin and vinblastine in advanced non small cell lung cancer. A multicenter, randomized phase III trial.

Paccagnella A, Favaretto A, Oniga F, Barbieri F, Ceresoli G, Torri W, Villa E, Verusio C, Cetto GL, Santo A, De Pangher V, Artioli F, Cacciani GC, Parodi G, Soresi F, Ghi MG, Morabito A, Biason R, Giusto M, Mosconi P, Chiarion Sileni V; GSTVP (Gruppo di Studio Tumori Polmonari del Veneto).

Lung Cancer. 2004 Jan;43(1):83-91.

PMID:
14698542
3.

Combined cisplatin, doxorubicin, and mitomycin for the treatment of advanced pleural mesothelioma: a phase II FONICAP trial. Italian Lung Cancer Task Force.

Pennucci MC, Ardizzoni A, Pronzato P, Fioretti M, Lanfranco C, Verna A, Giorgi G, Vigani A, Frola C, Rosso R.

Cancer. 1997 May 15;79(10):1897-902.

PMID:
9149015
4.

The palliative benefits of MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in patients with malignant mesothelioma.

Andreopoulou E, Ross PJ, O'Brien ME, Ford HE, Priest K, Eisen T, Norton A, Ashley S, Smith IE.

Ann Oncol. 2004 Sep;15(9):1406-12.

5.

BTS randomised feasibility study of active symptom control with or without chemotherapy in malignant pleural mesothelioma: ISRCTN 54469112.

Muers MF, Rudd RM, O'Brien ME, Qian W, Hodson A, Parmar MK, Girling DJ; British Thoracic Society Mesothelioma Group.

Thorax. 2004 Feb;59(2):144-8.

6.

Prospective study of combination chemotherapy with cyclophosphamide, doxorubicin, and cisplatin for unresectable or metastatic malignant pleural mesothelioma.

Shin DM, Fossella FV, Umsawasdi T, Murphy WK, Chasen MH, Walsh G, Komaki R, McMurtrey MJ, Hong WK.

Cancer. 1995 Dec 1;76(11):2230-6.

7.

Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.

Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P.

J Clin Oncol. 2003 Jul 15;21(14):2636-44.

PMID:
12860938
8.

Combination chemotherapy with cisplatin-vinblastine in malignant mesothelioma.

Tsavaris N, Mylonakis N, Karvounis N, Bacoyiannis C, Briasoulis E, Skarlos D, Pavlidis N, Stamatelos G, Kosmidis P.

Lung Cancer. 1994 Sep;11(3-4):299-303.

PMID:
7812707
9.

Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B.

Chahinian AP, Antman K, Goutsou M, Corson JM, Suzuki Y, Modeas C, Herndon JE 2nd, Aisner J, Ellison RR, Leone L, et al.

J Clin Oncol. 1993 Aug;11(8):1559-65.

PMID:
8336195
10.
11.

Thoracic stop-flow perfusion in the treatment of refractory malignant pleural mesothelioma: a phase I-II evaluation/trial.

Guadagni S, Clementi M, Valenti M, Fiorentini G, Cantore M, Kanavos E, Amicucci G.

In Vivo. 2006 Nov-Dec;20(6A):715-8.

12.

A phase II trial of pleurectomy/decortication followed by intrapleural and systemic chemotherapy for malignant pleural mesothelioma.

Rusch V, Saltz L, Venkatraman E, Ginsberg R, McCormack P, Burt M, Markman M, Kelsen D.

J Clin Oncol. 1994 Jun;12(6):1156-63.

PMID:
8201377
13.

Short-term treatment-related symptoms and quality of life: results from an international randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an EORTC Lung-Cancer Group and National Cancer Institute, Canada, Intergroup Study.

Bottomley A, Gaafar R, Manegold C, Burgers S, Coens C, Legrand C, Vincent M, Giaccone G, Van Meerbeeck J; EORTC Lung-Cancer Group; National Cancer Institute, Canada.

J Clin Oncol. 2006 Mar 20;24(9):1435-42. Epub 2006 Jan 30. Erratum in: J Clin Oncol. 2006 Jun 1;24(16):2601. Gaafa, Rabab [corrected to Gaafar, Rahab].

14.

Combination chemotherapy with mitoxantrone, methotrexate, and mitomycin (MMM regimen) in malignant pleural mesothelioma: a phase II study.

Pinto C, Marino A, Guaraldi M, Melotti B, Piana E, Martoni A, Pannuti F.

Am J Clin Oncol. 2001 Apr;24(2):143-7.

PMID:
11319288
15.
16.

Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma.

Jassem J, Ramlau R, Santoro A, Schuette W, Chemaissani A, Hong S, Blatter J, Adachi S, Hanauske A, Manegold C.

J Clin Oncol. 2008 Apr 1;26(10):1698-704. doi: 10.1200/JCO.2006.09.9887.

17.

Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma.

Manegold C, Symanowski J, Gatzemeier U, Reck M, von Pawel J, Kortsik C, Nackaerts K, Lianes P, Vogelzang NJ.

Ann Oncol. 2005 Jun;16(6):923-7. Epub 2005 Apr 11.

18.

Pemetrexed in the treatment of malignant mesothelioma: results from an expanded access program in Germany.

Reck M, Stahel RA, von Pawel J, Karthaus M, Korfee S, Serke M, Schuette WH, Eschbach C, Fink TH, Leschinger MI, Manegold C.

Respir Med. 2010 Jan;104(1):142-8. doi: 10.1016/j.rmed.2009.07.019. Epub 2009 Oct 8.

19.

Good symptom relief with palliative MVP (mitomycin-C, vinblastine and cisplatin) chemotherapy in malignant mesothelioma.

Middleton GW, Smith IE, O'Brien ME, Norton A, Hickish T, Priest K, Spencer L, Ashley S.

Ann Oncol. 1998 Mar;9(3):269-73.

20.

Combination of raltitrexed and oxaliplatin is an active regimen in malignant mesothelioma: results of a phase II study.

Fizazi K, Doubre H, Le Chevalier T, Riviere A, Viala J, Daniel C, Robert L, Barthélemy P, Fandi A, Ruffié P.

J Clin Oncol. 2003 Jan 15;21(2):349-54.

PMID:
12525529
Items per page

Supplemental Content

Write to the Help Desk